Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2007

View Archived Issues

Recent Tibotec, Medivir and Valeant patents report novel anti-hepatitis agents

Medivir reviews 2006

Studies detail stem cell mobilization efficacy of AMD-3100

Association between dopamine agonist use and pathological gambling in RLS

Novel anticancer compounds described in recent patents

Novel therapeutic agents for respiratory disorders described in recent patents

Novel therapeutic agents for transplant rejection disclosed by Astellas

New vaccine therapy may be useful to treat recurrent cancer in the elderly

Noscapine shows efficacy in prostate cancer

Genfit renews alliances

Schering-Plough begins phase I study of Pharmacopeia collaborative compound

Avalon begins drug discovery program targeting MYC oncoprotein

Treatment begins in pivotal program for LX-211 in uveitis

Shire to acquire New River Pharmaceuticals

Disruption of the CXCR4-CXCL12 and VLA4-VCAM-1 axes may sensitize leukemia cells to chemotherapy

Bentley cleared to begin phase II program for Nasulin in India

Athenagen changes name to CoMentis

MIST-B02 shows promise in pilot pharmacokinetic study

Hana anticipates delay in launch of Zensana

AA-4500 successful in treating Dupuytren's contracture

6R-BH4 shows no significant benefit over placebo in poorly controlled hypertension

SD-118 for neuropathic pain completes preclinical testing

Vascular disruption agent BNC-105 begins safety studies in animals

Allon files IND for AL-108 phase II trials in schizophrenia

FDA requests strengthened label warnings for Xolair

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...